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Abstract
Background: Persistent disabilities are key manifestations of Chikungunya virus (CHIKV) infection, especially
incapacitating polyarthralgia and fatigue. So far, little is known about their impact on health status. The present
study aimed at describing the burden of CHIKV prolonged or late-onset symptoms on the self-perceived health of
La Réunion islanders.
Methods: At 18 months after an outbreak of Chikungunya virus, we implemented the TELECHIK survey; a
retrospective cohort study conducted on a random sample of the representative SEROCHIK population-based
survey. A total of 1,094 subjects sampled for CHIKV-specific IgG antibodies in the setting of La Réunion island in
the Indian Ocean, between August 2006 and October 2006, were interviewed about current symptoms divided
into musculoskeletal/rheumatic, fatigue, cerebral, sensorineural, digestive and dermatological categories.
Results: At the time of interview, 43% of seropositive (CHIK+) subjects reported musculoskeletal pain (vs 17% of
seronegative (CHIK-) subjects, P < 0.001), 54% fatigue (vs 46%, P = 0.04), 75% cerebral disorders (vs 57%, P < 0.001),
49% sensorineural impairments (vs 37%, P = 0.001), 18% digestive complaints (vs 15%, P = 0.21), and 36% skin
involvement (vs 34%, P = 0.20) on average 2 years after infection (range: 15-34 months). After controlling for
confounders such as age, gender, body mass index or major comorbidities in different Poisson regression models,
33% of joint pains were attributable to CHIKV, 10% of cerebral disorders and 7.5% of sensorineural impairments,
while Chikungunya did not enhance fatigue states, digestive and skin disorders.
Conclusions: On average, 2 years after infection 43% to 75% of infected people reported prolonged or late-onset
symptoms highly attributable to CHIKV. These manifestations carry a significant burden in the community in the
fields of rheumatology, neurology and sensorineural health.
Background
Chikungunya virus (CHIKV) is an enveloped RNA posi-
tive-strand alphavirus belonging to the Togaviridae
family, transmitted by Aedes mosquitoes [1]. CHIKV is
now known to target human epithelial and endothelial
cells, fibroblasts and macrophages [2], human muscle
satellite cells [3], and to cause a wide range of acute
manifestations including fever, arthralgia, myalgia, rash
and fatigue [4,5]. Furthermore, CHIKV infection often
leads to prolonged joint pain, whose stability or relapses
characterize the hallmark symptom of ‘Chikungunya
rheumatism’ [5-7]. The basis of musculoskeletal pain
and chronic arthropathy observed after acute CHIKV
infection may come from the early escape of CHIKV
from blood monocytes [8], allowing its relocation to
synovial macrophages, as seen with the Ross River virus
(RRV) [9], rather than from autoimmunity. The persis-
tence of CHIKV in such sanctuaries triggers a sustained
low-noise T helper 1 cell (Th1) response leading to
chronic inflammation and fibrosis, as shown by recent
findings in a non-human primate model [10]. Such a
pathway has been previously outlined by a single case
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ies, both from La Réunion Island infected individuals
[11,12].
Beyond these common features, CHIKV infection also
exhibits more atypical forms [13,14]. These include cere-
bral disorders resulting from a now well established
neurotropism [15,16], ranging from mild disrupted
behavior or altered mental status to severe encephalopa-
thy/encephalitis [16-19] and to various sensorineural
impairments [20,21]. Concurrently, CHIKV infection is
known to account for a broad spectrum of mucocuta-
neous lesions [22,23]. Interestingly, investigation of the
pathogenesis, natural course and clinical impact has so
far been neglected.
These prolonged or late-onset symptoms occur either
at the acute stage or during convalescence and their clini-
cal picture is neither specific nor consistent between
individuals. Whether these manifestations are directly
attributable to CHIKV infection or represent the exacer-
bation or complications of underlying conditions, such as
osteoarthritis [7], or account for the mode of entry of a
subsequent chronic disease, such as rheumatoid arthritis
(RA) or psoriatic rheumatism [24,25], is still unknown.
Moreover, their clinical burden for the community has
not been researched beyond a small and non-representa-
tive matched cohort study [26].
To address these important topics, we designed the
TELECHIK survey, a telephonic interview through the
framework of the SEROCHIK survey. The goal of the
SEROCHIK survey was to clarify the seroprevalence and
the risk factors of CHIKV infection within the commu-
nity of La Réunion in the context of the large-scale epi-
demic that swept the island in 2005-2006 [27,28]. The
current study assesses the self-perceived morbidity by La
Réunion islanders but also reveals the public health
impact of Chikungunya disease in showing the true areas
of the community burden, on average 18 months after
the outbreak incident.
Methods
Study design and population
Participants were enrolled in a retrospective cohort study,
the TELECHIK survey, designed from the framework of
the cross-sectional, population-based SEROCHIK survey
[27,28]. The latter, conducted in La Réunion between 17
August and 20 October 2006 soon after an outbreak of
Chikungunya virus (June 2006), involved a representative
sample of 2,442 index individuals for whom their medical
history in relation to Chikungunya was sought and a spe-
cific serological enzyme-linked immunosorbent assay
(ELISA) test performed [27].
Exposure to CHIKV was defined as positive for the
subjects with positive CHIKV-specific IgG antibodies.
Seropositive (CHIK+) and seronegative (CHIK-) subjects
were allocated by classifying the previous exposure item
within six strata defined at the time of the SEROCHIK
survey as follows: true positive (TP, symptomatic CHIK
+), false negative (FN, asymptomatic CHIK+), not know-
ing positive (NKP, CHIK+ without memories of symp-
toms and serostatus), true negative (TN, asymptomatic
CHIK- negative), false positive (FP, symptomatic CHIK-
), not knowing negative (NKN, CHIK- without reminis-
cence of symptoms and serostatus) in order to account
for the declaration bias beyond the representativeness of
our cohort. Taking into account a feasibility constraint,
t w os u b s e t so ft h es a m es i z eo fT Pa n dT Ns u b j e c t s
were randomly selected after stratification for age, gen-
der and area of residence, with the aim to control the
repartition bias. This allocation was conducted by apply-
ing reasoned sampling fractions (TP: 0.7 and TN: 0.46),
while FP, NKP, FN, NKN, and fewer at SEROCHIK
inclusion, were all systematically selected.
Setting
La Réunion is a French overseas ‘département’ of 805,500
inhabitants, located on a volcanic island of 2,511 km
2
belonging to the Mascarene archipelago in the southwes-
tern Indian Ocean. In 2005-2006, La Réunion was, for the
first time in its history, overwhelmed by a Chikungunya
epidemic of unprecedented magnitude. More than 266,000
clinical cases were noted by the public health authorities
and nearly 300,000 inhabitants (38.2%) were considered to
have been infected [27]. The main reason for such wide-
spread emergence of CHIKV was a single mutation in the
envelope protein gene (E1-A226V) that increased the fit of
the virus for its principal vector, Aedes albopictus,t h e
Asian tiger mosquito [29,30]. Furthermore, Ae albopictus,
was known to exhibit an unusual adaptive property to the
human host (so-called anthropization) in La Réunion for a
period [31], which was later highlighted by the recent
entomological surveys [32].
Data collection
Participants were interviewed by telephone between
November 2007 and May 2008. A short questionnaire
was administered by one blinded investigator (CM) to
ensure the best possible reproducibility. It was com-
posed of closed questions addressing the most currently
reported symptoms. The latter accounted for musculos-
keletal pain, headache, digestive disorders, sleeping dis-
orders, memory troubles, attention difficulties, mood
disturbance, depression, blurred vision, hearing difficul-
ties, skin lesions, and alopecia.
Body mass index (BMI) was calculated as weight (kg)
divided by the square of height (m
2). Weight and height,
as all the relevant comorbidities, were reported from the
SEROCHIK survey. Parents or legal guardians were
interviewed for persons aged under 15 years.
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The sample size was determined to enable the detection
of a minimum 10% difference between infected (CHIK+)
TP and uninfected (CHIK-) healthy TN subjects in
musculoskeletal pain frequency, assuming a one-sided
type I error of 5% and a power of 90%. The more con-
servative scenario, depicting a baseline incidence of
musculoskeletal pain between 40% and 50% in the adult
TN population, as suggested by those observed in the
general UK population [33], and between 50% and 60%
in the TP adult population (CHIK+ patients), required
560 TP, 560 TN, all the FP, NKP, FN, and NKN sub-
jects, assuming a loss level of 33%, due to incomplete
data plus non-responders.
Assessment of current symptoms according to explana-
tory variables was conducted by bivariate analysis.
Proportions were compared using corrected design-based
c
2 tests and means using the adjusted Wald test as
appropriate. Symptoms were categorized as musculoske-
letal/rheumatic, fatigue, light cerebral (headache, and/or
sleep disorders, memory troubles, attention difficulties,
mood disturbance, depression), sensorineural (blurred
vision, hearing difficulties), digestive (digestive disorders)
and dermatological (skin lesions, alopecia). Crude preva-
lence ratios (cPR) and 95% confidence intervals (95%
CIs) of CHIKV infection were generated using Poisson
regression models for each symptom and category. The
crude etiology fraction (EF) and 95% CI of CHIKV infec-
tion was calculated for each category linked to Chikungu-
nya to assess the accountability of CHIKV in the genesis
of an area of symptoms, as follows: EF (%) = (π1 - π0/π1)
× 100, with π1 the prevalence of the symptom among
CHIK+ subjects and π0: the prevalence of the symptom
among CHIK- subjects. Adjusted prevalence ratios (aPR)
and 95% CIs for Chikungunya were calculated in Poisson
regression models controlling major confounders such as
age, gender, BMI, and comorbidities. The population
attributable risk (PAR) of CHIKV infection was calcu-
lated to assess the community burden of Chikungunya
within the perceived morbidity on a population basis. To
account for a possible subjectivity bias inherent of FP,
NKP, FN, and NKN subjects, we did a sensitivity analysis
in the sample restricted to TP and TN. To determine
whether the knowledge of previous exposure may affect
self-perceived morbidity later on follow-up, we also com-
pared the declaration of each symptoms within FP and
FN subsets, assuming that the subjectivity inherent to FP
be expressed steadily over time. Finally, we tested the
hypothesis that for CHIK+ TP subjects, a previous
declaration of intense symptoms (defined as reports of
fever plus arthralgia and/or myalgia at the onset of infec-
tion) was associated with a more frequent symptoms
declaration on follow-up, assuming that subjectivity
would not change the expected gradient of declarations
from TN to intense TP (TN < mild TP < intense TP). For
all theses analyses, we took special care to verify that the
timing of questioning was similar across the groups, and
the multiple stage complex sampling procedure was
taken into account. Statistical significance was set at
P = 0.05. EpiData software (v.3.1; EpiData, Copenhagen,
Denmark) was used for data entry and Stata (v.10.0; Sta-
taCorp, College Station, TX, USA) for the analysis.
Ethical considerations
During the SEROCHIK survey, which had previously
received ethical approval from the ethical committee for
studies with human subjects (CPP) of Bordeaux and the
National Commission for Informatics and Liberty
(CNIL) [27], the participants had been informed that
they might be called back for ancillary research [26].
During the telephone interview, the objectives of the
TELECHIK survey were presented and oral consent to
participate was obtained.
Results
Among the 1,542 individuals selected, 5 had died since
the SEROCHIK survey (no death certificate mentioned
Chikungunya as the leading cause for death; source:
cepiDC, INSERM, France), 359 had missing contact
details, 20 refused to answer the questionnaire and 54
were excluded from the analysis because of incomplete
data or mismatched responders (different from the
index person, parents, legal guardian); thus, 1,094 index
individuals were retained for analysis (Figure 1).
The mean age of the participants was 36 years (range:
1 month to 93 years); 39% of subjects were aged less
than 30 years, 48% were 30 to 59 years and 13% were
60 years or older. The male to female ratio was 0.74.
The distribution of the area of residence was representa-
tive of the one observed in the community (Table 1). More
females were participants compared to non-participants
(59.0% vs 52.7%, P = 0.02), while age and residential area
did not differ.
Overall, following a mean time of 16 months from the
SEROCHIK survey (range: 13-20 months, on average
1 5 . 9 3m o n t h sf o rC H I K +v s1 5 . 9 7m o n t h sf o rC H I K - ,
P = 0.60), 80.9% of the 1,094 participants interviewed
for the TELECHIK survey reported 1 or more symp-
toms. The time elapsed between infection and telephone
interview in CHIK+ subjects is given in Additional file 1.
Among infected individuals, the 413 TP subjects (med-
ian time between infection and interview: 23.7 months,
Q1-Q3: 21.9-24.9 months, mode: 25 months, range: 15-34
months) did not differ from 67 FN and 32 NKP subjects
on age, gender, BMI and major comorbidities, which
allowed the consolidation of the 3 groups into 1 of 512
CHIK+ subjects. Similarly, among uninfected peers, even
though 396 TN subjects were younger than 81 FP or
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several comorbidities, TN, FP, and NKN subjects were
also regrouped into 1 group (CHIK-) to simplify the
comparisons.
The crude PRs and 95% CIs for CHIKV infection for
the current self-reported symptoms and categories of
symptoms are shown in Table 2. CHIK+ subjects were
more likely than CHIK- peers to complain of musculos-
keletal pain (43% vs 17%, Crude PR: 2.5, 95% CI 1.9 to
3.1) with a high proportion attributable to CHIKV infec-
tion (EF: 60.0%, 95% CI 51.8% to 68.2%). CHIK+ sub-
jects also more frequently reported fatigue, light cerebral
disorders, and sensorineural impairment than their
CHIK- peers. The EF of CHIKV infection was 13.5%
Figure 1 Study participation profile of the TELECHIK cohort study. Exposure was defined using Chikungunya virus (CHIKV)-specific IgG
antibodies and self-report of common symptoms within six strata: FN = false negative, FP = false positive, NKN = not knowing negative, NKP =
not knowing positive, TN: true negative, TP: true positive. *In all, 8 questionnaires were excluded for poor quality responses (impossibility of
interpretation), and 46 were excluded for responders different from the index individual, parents or legal guardian in the TELECHIK survey.
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to 30.8%) for light cerebral disorders and 23.8% (95% CI
13.3 to 34.3%) for sensorineural impairment.
Digestive and skin disorders (including alopecia) were
not associated with Chikungunya infection. Among the
light cerebral disorders, the most closely linked to
CHIKV infection were attention difficulties (EF: 46.3%,
95% CI 35.7% to 57.0%), memory trouble (EF: 39.9%,
95% CI 29.5% to 50.2%), mood disturbance (EF: 38.3%,
95% CI 27.0% to 49.5%) and depression (EF: 45.6%, 95%
CI 26.8% to 64.4%), whereas the association with head-
ache (EF: 22.6%, 95% CI 5.7% to 39.5%) and sleep disor-
ders (EF: 22.9%, 95% CI 8.0% to 37.8%) was slight.
Among sensorineural impairments, Chikungunya infec-
tion affected vision (blurred vision, EF: 28.2%, 95% CI
16.7% to 39.7%) more than hearing (hearing difficulties,
EF: 26.7%, 95% CI 6.2% to 47.3%). Consistently, the sen-
sitivity analysis restricted to TP and TN (Additional file 2)
depicted the same figures with stronger links, which
argued for a causative role of CHIKV in the pathogen-
esis of symptoms (this time including hearing loss,
P = 0.016), and indirectly for subjectivity in FP, NKP,
FN, and NKN subsets. Against all odds, the FP subjects
tended to declare almost every symptom more fre-
quently than the FN subjects on follow-up, which
argued for influence of subjectivity rather than knowl-
edge of exposure in self-perceived morbidity at a dis-
tance. As expected, the TP subjects with the more
intense symptoms at onset of infection complained
slightly more frequently on follow-up than mild TP sub-
jects, and far more than TN subjects, confirming the
link between intense inaugural symptoms and late man-
ifestations, as the minor role of subjectivity in CHIK+
subjects.
The adjusted PRs and 95% CIs inherent of CHIKV
infection and major confounders for determining
Table 1 Characteristics of the 1,094 subjects analyzed for
current health status at follow-up TELECHIK survey,
November 2007 to May 2008, and of La Réunion Island
population
Characteristics, n (%) TELECHIK INSEE
a
Gender:
Women 645 (57.4) 414,855 (51.5)
b
Men 449 (42.6) 390,645 (48.5)
Age, years:
<20 214 (27.6) 281,680 (35.0)
b
20 to 29 124 (11.8) 106,277 (13.2)
30 to 39 159 (16.3) 118,412 (14.7)
40 to 49 180 (17.6) 123,616 (15.3)
50 to 59 187 (14.2) 84,122 (10.4)
60 to 69 133 (7.7) 49,397 (6.1)
≥70 years 97 (4.8) 41,996 (5.2)
Residential area:
c
North 249 (22.8) 190,625 (24.4)
d
East 167 (15.3) 114,278 (14.6)
South 403 (36.8) 277,602 (35.5)
West 275 (25.1) 199,457 (25.5)
a Institut National de la Statistique et des Etudes Economiques;
b2008 census;
cLa Réunion Island is divided into four administrative microregions: North,
East, South, and West;
d2006 census.
Table 2 Crude weighted rates and prevalence ratios of self-reported symptoms/CHIKV status, TELECHIK survey, La
Réunion Island population, November 2007 to May 2008
Symptoms (%) Seronegative (CHIK-), % Seropositive (CHIK+), % Crude prevalence ratio 95% CI P value
Musculoskeletal pain 17.1 42.8 2.5 1.9 to 3.1 <0.001
Fatigue 46.4 53.6 1.1 1.0 to 1.3 0.04
Light cerebral disorders 57.0 75.3 1.3 1.1 to 1.5 <0.001
Headache 20.0 25.9 1.3 1.0 to 1.7 0.05
Sleep disorders 24.1 31.2 1.3 1.0 to 1.7 0.02
Memory troubles 25.4 42.2 1.7 1.3 to 2.0 <0.001
Attention difficulties 19.9 37.1 1.9 1.4 to 2.3 <0.001
Mood disturbance 23.7 38.4 1.6 1.3 to 2.0 <0.001
Depression 8.0 14.7 1.8 1.2 to 2.7 0.002
Sensorineural disorders 37.2 48.8 1.4 1.1 to 1.5 0.001
Blurred vision 30.2 42.0 1.4 1.1 to 1.7 <0.001
Hearing difficulties 13.0 17.8 1.4 0.9 to 1.9 0.05
Digestive disorders 15.0 18.3 1.2 0.8 to 1.7 0.21
Dermatological disorders 34.2 36.1 1.2 0.8 to 1.7 0.205
Skin lesions 17.2 19.9 1.2 0.8 to 1.5 0.33
Alopecia 21.4 21.9 1.0 0.7 to 1.3 0.835
The weighted rates of the symptoms are expressed as percentages. Chikungunya status is defined by specific anti-CHIKV IgG antibodies.
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and sensorineural impairment are shown in Tables 3, 4,
5, 6.
When adjusting for major confounders, on average
24 months (range: 15-34 months) after the acute stage
of the infection CHIK+ subjects were twice as likely to
report musculoskeletal pain (aPR: 2.1, 95% CI 1.7 to 2.7)
than their CHIK- counterparts (Table 3). Furthermore,
they complained more easily of light cerebral disorders
(aPR: 1.3, 95% CI 1.2 to 1.4) (Table 5). Similarly, they
were also slightly associated with sensorineural impair-
m e n t( a P R :1 . 2 ,9 5 %C I1 . 0t o1 . 4 )( T a b l e6 ) .A c c o r d -
ingly, the same models applied to TP and TN subjects
(Additional files 3, 4, 5) drew similar conclusions favor-
ing the role of CHIKV, except those dedicated to fati-
gue. Fatigue was not enhanced in CHIK+ subjects
compared with CHIK- peers (aPR: 1.1, 95% CI 0.9 to
1.3) when considering the whole sample (Table 4),
whereas it was linked to infection (aPR: 1.2, 95% CI 1.0 to
1.4, P = 0.025) in TP and TN subjects (Additional file 6).
Importantly, the PARs for Chikungunya to explain
musculoskeletal pain, light cerebral disorders and sen-
sorineural impairment, as expressed by the community,
were respectively 33.6%, 10.4% and 7.5%. In other
words, if Chikungunya had been fully preventable, parti-
cipants should have reported two-thirds of the muscu-
loskeletal pains, 89.6% of the light cerebral disorders
and 92.5% of the sensorineural impairments declared in
the TELECHIK survey.
Discussion
Here, we report a large follow-up study dealing with the
community burden of Chikungunya long-term manifes-
tations, experienced within the La Réunion population
after the 2005-2006 Chikungunya virus outbreak
[6,7,12]. One of the major findings of our population-
based survey is that self-perceived morbidity, described
through several subjective symptoms and categories of
manifestations (musculoskeletal pain, fatigue, light cere-
bral disorders, sensorineural impairment, digestive and
skin disorders), on average 18 months after the out-
break, is still largely attributed to Chikungunya. Thus,
among previously exposed individuals (CHIK+ subjects),
CHIKV would be involved in 60% of musculoskeletal
pains (characterized indistinctively as joint, bone or
muscle aches), approximately a quarter of cerebral
Table 3 Adjusted prevalence ratios for the determinants
of self-reported rheumatic symptoms, TELECHIK survey,
La Réunion Island population, November 2007 to May
2008
Determinants Adjusted prevalence ratio 95% CI P value
Chikungunya: <0.001
No 1
Yes 2.1 1.7 to 2.7
Gender: 0.08
Male 1
Female 1.2 0.9 to 1.5
Age, years: <0.001
<20 1
20 to 29 1.4 0.7 to 2.5
30 to 39 1.8 1.1 to 3.0
40 to 49 2.7 1.7 to 4.2
50 to 59 3.3 2.1 to 5.2
60 to 69 3.9 2.5 to 6.1
≥70 3.5 2.2 to 5.6
Body mass index,
kg/m
2:
0.001
<25 1
25-29.9 1.5 1.2 to 1.8
≥30 1.3 0.9 to 1.7
Comorbidity:
a 0.11
None 1
Osteoarthritis 1.4 1.0 to 2.0
Other
a 1.2 0.9 to 1.5
a Diabetes mellitus, hypertension, ischemic heart disease, asthma, chronic
obstructive pulmonary disease, renal failure, cancer.
Table 4 Adjusted prevalence ratios for the determinants
of fatigue, TELECHIK survey, La Réunion Island
population, November 2007 to May 2008
Determinants Adjusted prevalence ratio 95% CI P value
Chikungunya: 0.11
No 1
Yes 1.1 0.9 to 1.3
Gender: <0.001
Male 1
Female 1.4 1.1 to 1.6
Age, years: 0.003
<20 1
20 to 29 1.7 1.2 to 2.2
30 to 39 1.5 1.1 to 2.0
40 to 49 1.5 1.1 to 2.0
50 to 59 1.5 1.1 to 2.0
60 to 69 1.4 1.0 to 1.8
≥70 1.7 1.2 to 2.3
Comorbidity:
a 0.006
None 1
1 1.2 1.0 to 1.5
2 1.1 0.8 to 1.4
≥3 1.5 1.2 to 1.8
a Osteoarthritis, diabetes mellitus, hypertension, ischemic heart disease,
asthma, chronic obstructive pulmonary disease, renal failure, cancer.
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fatigue states. Moreover, at the general population level,
after controlling major confounders, Chikungunya could
explain a third of rheumatic symptoms, 10% of neurolo-
gical and 7.5% of sensorineural complaints. These fea-
tures highlight a previously misrecognized impact of
CHIKV infection in the fields of rheumatology, neurol-
ogy and sensorineural health.
To the best of our knowledge, beyond a smaller non-
representative matched cohort study [26], no comparative
study to date had attempted to establish the responsibility
of Chikungunya for the persistence (or the delayed onset)
of non-specific common symptoms, nor its public health
impact. To address these questions we designed the TELE-
CHIK study, a comparison set beyond the framework of
the population-based SEROCHIK survey that allowed the
selection of a random sample of the La Réunion island
community [27,28]. Moreover to enable a random homo-
geneous allocation of subjectivity determinants of the
symptoms reported, we also adjusted for major confoun-
ders of health status in order to assess the proper role of
CHIKV infection in perceived morbidity. These restric-
tions, both in design and analysis, were necessary to make
a causal relationship plausible between CHIKV and its
related manifestations. Indeed, they are now recognized as
an indisputable prerequisite to improve the standard of
proof of observational studies [34].
The reality of ‘Chikungunya rheumatism’ was suggested
formerly in a few case report series [35-37]. It has also
been supported in recent years by several observational
studies [4-7,38,39], whose design should not have defi-
nitely attributed such non-specific symptoms to CHIKV.
For instance, in Transvaal, South Africa, 15% of patients
complained of persistent arthralgia 20 months after
acute infection [35], while 12% reported recurrent relap-
sing joint pain, stiffness or swelling 3 to 5 years after
Chikungunya onset [36]. Nonetheless, these assessments
were not conducted with any formal evaluation of the
community burden of such symptoms. In contrast, cases
imported to France from La Réunion exhibited a heavier
burden with rheumatic manifestations of at least 48%
6 months to 2 years after the acute infection [38,39].
Of note, among La Réunion islanders, the persistence
of rheumatic pain was perceived to be at a similarly
alarming level, with 57% of CHIK+ subjects from a non-
representative sample of the population experiencing
permanent or recurrent polyarthralgia after a course of
15 months [7]. Consistently, the figure rose to 64% in
hospitalized CHIK+ patients at 18 months post infection
[6]. However, in all these studies, the causality between
Table 6 Adjusted prevalence ratios for the determinants
of sensorineural impairment, TELECHIK survey, La
Réunion Island population, November 2007 to May 2008
Determinants Adjusted prevalence ratio 95% CI P value
Chikungunya: 0.02
No 1
Yes 1.2 1.0 to 1.4
Gender: 0.36
Male 1
Female 1.1 0.9 to 1.3
Age, years: <0.001
<20 1
20 to 29 1.7 1.0 to 2.5
30 to 39 1.4 0.9 to 2.1
40 to 49 2.6 1.9 to 3.6
50 to 59 2.7 1.9 to 3.7
60 to 69 2.7 1.9 to 3.8
≥70 2.6 1.7 to 3.7
Comorbidity:
a 0.20
None 1
1 1.1 0.9 to 1.3
2 1.2 0.9 to 1.5
≥3 1.3 0.9 to 1.6
a Osteoarthritis, diabetes mellitus, hypertension, ischemic heart disease,
asthma, chronic obstructive pulmonary disease, renal failure, cancer.
Table 5 Adjusted prevalence ratios for the determinants
of light cerebral disorders, TELECHIK survey, La Réunion
Island population, November 2007 to May 2008
Determinants Adjusted prevalence ratio 95% CI P value
Chikungunya: <0.001
No 1
Yes 1.3 1.1 to 1.4
Gender: 0.002
Male 1
Female 1.2 1.0 to 1.3
Age, years: 0.83
<20 1
20 to 29 1.1 0.8 to 1.3
30 to 39 0.9 0.8 to 1.2
40 to 49 1.0 0.8 to 1.2
50 to 59 1.1 0.9 to 1.3
60 to 69 1.0 0.8 to 1.2
≥70 0.9 0.7 to 1.2
Comorbidity:
a 0.04
None 1
1 1.1 0.9 to 1.3
2 1.2 1.0 to 1.4
≥3 1.2 0.9 to 1.6
a Osteoarthritis, diabetes mellitus, hypertension, ischemic heart disease,
asthma, chronic obstructive pulmonary disease, renal failure, cancer.
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was questionable, either due to participation and selec-
tion biases, to absence of standardization in symptom eli-
citation, to lack of clinical review, and to the absence of
an uninfected control group to assess symptom rates at
baseline.
Infections with other ‘arthritogenic’ alphaviruses such as
RRV or Sindbis-related (Pogosta) virus were associated
with same magnitude of incidence (50% to 60%) of persist-
ing arthralgia 6 months to 3 years after acute infection
[40-43]. Interestingly, half of the cohort of RRV patients
exhibited signs over time of chronic rheumatic disease
[44]. Similarly, Borgherini et al. reported that 44% of
Réunionese patients declaring prolonged Chikungunya
arthritis had a previous history of joint pain [6]. Accord-
ingly, Sissoko et al. identified the presence of underlying
osteoarthritis (OA) comorbidity as a significant risk factor
for non-recovery [7]. This is why the possibility of overlap
between a rheumatic pre-existing underlying condition
and an authentic Chikungunya-specific arthralgia led the
more skeptical contributors to think that prolonged signs
of ‘arthritogenic’ alphaviruses could represent the mode of
revelation of chronic rheumatic diseases, such as RA or
psoriatic rheumatism [6,23,24,42,43].
Our study has shown that among CHIKV infected
individuals, 60% of polyarthralgia could be attributed to
CHIKV. The understanding of the musculoskeletal
symptoms of Chikungunya has taken a significant step
forward with the recent development of a non-human
primate model [10]. These data confirm the central
place of the macrophage as the main target cell for
CHIKV dissemination and persistence within the organ-
ism, as well as being the cornerstone for CHIKV rheu-
matic pathophysiology [8,11,12]. Thus, similarly to RRV
or RA [9], an inadequate host innate immune (Th1)
response to CHIKV could damage cartilage and be the
source of OA degenerative lesions [45]. With regard to
the potential community burden of Chikungunya-
specific rheumatism, efforts should focus on the control
of Chikungunya joint damage with pre-existing or newly
developed anti-inflammatory drugs [9,24,46]. For these
reasons, further research including randomized clinical
trials are required to better understand the mechanisms
of CHIKV pathophysiology and promote the prevention
of the progression of OA in areas affected by this
‘arthritogenic’ virus.
The fact Chikungunya is responsible for so many
issues, involved in 13.5% of fatigue states and in 24.2% of
light cerebral disorders, is not surprising. On the one
hand, CHIKV neurotropism is now well documented
through various observations at all ages of life [15-19].
Moreover, there is a growing body of evidence for the
presence of neuropathic pain in non-responsive CHIKV
patients associated with a more aggressive clinical picture
and more challenging treatment, which can impair qual-
ity of life and even lead to depression [47]. On the other
hand, some evidence supports the putative role of the
interferon family, and more widely of Th1 cytokines in
primary and drug-induced sickness behavior syndromes
[ 4 8 ] .I n t e r e s t i n g l y ,t h et w oc onditions include tiredness
and mood disturbance, both previously related to RRV
through the postinfective fatigue syndrome [49,50].
Indeed, Th1 cytokines are known to preferentially target
neurocircuits relevant to psychomotor activity (for exam-
ple, basal ganglia) [51]. Whether fatigue and light cere-
bral disorders in the context of CHIKV disease could
share a common neuropathogenesis involving the innate
immune system with RRV and other alphaviruses [48], or
represent the harmful consequences on psychomotor
activity of a long-lasting disease, deserves further
research. Nonetheless, there is undoubtedly potential for
a significant community burden of CHIKV neurotropism
that can no longer be ignored.
Little attention was paid to sensorineural impairment
before the recent Chikungunya epidemic. Thus, no
observational study has yet focused on ophthalmic and
hearing involvements beyond the few case series
reported from the Indian subcontinent [20,21]. Our data
demonstrate clearly that sensorineural health can be
affected during large-scale CHIKV outbreaks, through
v a r i o u sc o m p l a i n t ss u c ha sh e a r i n gd i f f i c u l t i e sa n d
blurred vision, independently of other conditions such
as senescence and diabetes mellitus. The basis of these
sensorial symptoms is still poorly understood and might
depict another facet of CHIKV neurotropism rather
than a direct targeting of sensory cells per se.
Taken together, with regard to the other aspects of
severe Chikungunya disease over the epidemic, such as
maternal-fetal transmission [16], myocarditis, Guillain-
Barré syndrome [18,19] or other atypical forms with
increased background mortality [13,14], the toll of long-
term disabilities reported herein supports enhanced
virulence of the E1-A226V strain compared to other
CHIKV strains involved in previous Asian outbreaks
[52], which argues definitively for revisiting Chikungunya
as a benign non-fatal illness.
Our study has some strengths and limitations. The
investigator was blinded to the serological status of the
participants to limit the propensity of classification bias
(overestimation of symptoms among CHIK+ subjects).
Though participants were interviewed long after the
onset of the disease, only ongoing symptoms were con-
sidered to minimize recall bias. In contrast with previous
studies, a control group was used for comparison and
subjects were randomly selected through a population-
based representative cohort [27]. Thus, there was no sub-
stantial participation bias favoring patients with severe
illness unlike previous hospital-based studies (non-
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The diagnostic accuracy was definitely efficient, as shown
by low proportions of asymptomatic cases and false posi-
tives [26,27]. Finally, we applied population weights to
account for the case-mix representativeness and mini-
mize the imbalance produced by selecting more women
and older participants. However, patients were not exam-
ined physically by clinicians either to rule out differential
diagnoses or to assess and confirm the complaints. More-
over, health perceptions may have been disturbed after
such a public health catastrophe [53]. These reasons may
have skewed the estimationo fs o m eo ft h es u b j e c t i v e
symptoms assessed in this survey of perceived morbidity.
This said, the role of subjectivity could be considered as
negligible in this study except for fatigue, as shown by
the sensitivity analysis restricted to true positives and
true negatives. It is also unlikely that subjectivity or the
k n o w l e d g eo fe x p o s u r ec h a n g e dt h eo v e r a l lm e a n i n go f
our findings owing to the small proportions of false posi-
tives and false negatives in the community [27], and of
participants not knowing their serostatus enrolled in the
TELECHIK survey. Nevertheless, it is important to
emphasize that the disease burden in terms of common
manifestations may be overstated by subjectivity and pre-
vious knowledge of exposure, especially for an emerging
arboviral infection when it is associated with illness-
specific catastrophic thinking [54]. Although this phe-
nomenon seems to us to be relatively marginal, it cannot
be ruled out because Chikungunya was ranked third
(after AIDS and cancer) on the scale of health risk
perceptions shortly after the outbreak (Perrau J et al.,
personal communication).
Conclusions
On average, 2 years after onset of infection 43% to 75% of
CHIK+ patients report prolonged or late-onset symptoms
highly attributable to CHIKV. These manifestations carry
a significant burden in the community in the fields of
rheumatology, neurology and sensorineural health. Our
findings lend support to clinical descriptions, pathophy-
siology, and perception of Chikungunya disease and give a
valuable insight towards the understanding of the eco-
nomic impact of this disabling arboviral disease.
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reported Chikungunya disease with no infection confirmed by CHIKV-
specific IgG antibodies); TP = true positive (self-reported Chikungunya
disease with infection confirmed by CHIKV-specific IgG antibodies).
Additional file 3: Table S2. Adjusted prevalence ratios for the
determinants of self-reported rheumatic symptoms, TELECHIK survey, La
Réunion Island population, November 2007 to May 2008. *Diabetes
mellitus, hypertension, ischemic heart disease, asthma, chronic
obstructive pulmonary disease, renal failure, cancer. TN = true negative
(no self-reported Chikungunya disease with no infection confirmed by
Chikungunya virus (CHIKV)-specific IgG antibodies); TP = true positive
(self-reported Chikungunya disease with infection confirmed by CHIKV-
specific IgG antibodies).
Additional file 4: Table S3. Adjusted prevalence ratios for the
determinants of light cerebral disorders, TELECHIK survey, La Réunion
Island population, November 2007 to May 2008. *Osteoarthritis, diabetes
mellitus, hypertension, ischemic heart disease, asthma, chronic
obstructive pulmonary disease, renal failure, cancer. TN = true negative
(no self-reported Chikungunya disease with no infection confirmed by
Chikungunya virus (CHIKV)-specific IgG antibodies); TP = true positive
(self-reported Chikungunya disease with infection confirmed by CHIKV-
specific IgG antibodies).
Additional file 5: Table S4. Adjusted prevalence ratios for the
determinants of sensorineural impairment, TELECHIK survey, La Réunion
Island population, November 2007 to May 2008. *Osteoarthritis, diabetes
mellitus, hypertension, ischemic heart disease, asthma, chronic
obstructive pulmonary disease, renal failure, cancer. TN = true negative
(no self-reported Chikungunya disease with no infection confirmed by
Chikungunya virus (CHIKV)-specific IgG antibodies); TP = true positive
(self-reported Chikungunya disease with infection confirmed by CHIKV-
specific IgG antibodies).
Additional file 6: Table S5. Adjusted prevalence ratios for the
determinants of fatigue, TELECHIK survey, La Réunion Island population,
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hypertension, ischemic heart disease, asthma, chronic obstructive
pulmonary disease, renal failure, cancer. TN = true negative (no self-
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(self-reported Chikungunya disease with infection confirmed by CHIKV-
specific IgG antibodies).
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